PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
204.50
Positive P/E while CRVO shows losses. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-214.06
Negative equity while CRVO shows P/B of 60.33. Joel Greenblatt would examine balance sheet repair potential.
1843.78
Positive FCF while CRVO shows negative FCF. John Neff would investigate cash generation advantage.
1843.78
Positive operating cash flow while CRVO shows negative OCF. John Neff would investigate operational advantage.
-214.06
Negative fair value while CRVO shows ratio of 60.33. Joel Greenblatt would examine valuation model differences.
0.12%
Positive earnings while CRVO shows losses. John Neff would investigate earnings advantage.
0.05%
Positive FCF while CRVO shows negative FCF. John Neff would investigate cash generation advantage.